Compare AIIO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIIO | PBYI |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United Arab Emirates | United States |
| Employees | 29 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.1M | 413.3M |
| IPO Year | N/A | 2011 |
| Metric | AIIO | PBYI |
|---|---|---|
| Price | $3.20 | $8.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 886.9K | 314.0K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $111.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $4.30 |
| 52 Week High | $9.20 | $9.40 |
| Indicator | AIIO | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 67.20 |
| Support Level | $2.60 | $7.44 |
| Resistance Level | $4.96 | N/A |
| Average True Range (ATR) | 0.25 | 0.40 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 51.08 | 75.13 |
Robo.ai Inc is a decentralized, AI-powered intelligent mobility platform that integrates smart vehicles, robotics, and blockchain technologies. The company is developing an AI-NAS ecosystem focused on delivering a passenger-centric platform by combining hardware and software, leveraging onboard computing, and offering an open cloud environment. Its product portfolio includes MUSE, a full-sized autonomous electric SPV; GHIATH, a purpose-built vehicle for public services and law enforcement developed in collaboration with Dubai Police; and Astra, an autonomous logistics vehicle. It also offers other vehicle models such as NWONE (SUV), Rabdan One (SUV), and Rabdan Seven (MPV) in the UAE through the SKD model. The company operates across the USA, UAE, and Mainland China.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.